Leader in sequence search provides flagship solution to developer of anti-infective disease therapies.

Westborough, Massachusetts - April 17, 2007 – GenomeQuest, Inc., a leader in sequence search for research and IP, today announced that it is providing its flagship GenomeQuest™ solution to MIGENIX, Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases.

GenomeQuest™ is a sequence search solution that enables biologists to evaluate novel gene sequences, and allows IP lawyers to evaluate freedom-to-operate, patentability, and competitive landscape features for the same sequences. The solution uniquely combines easy-to-use sequence search and analytics with public and proprietary sequence content, including the industry's largest and most complete indexed archive of close to 50 million patented sequences.

Dr. Dale R. Cameron, Director of Research (Anti-Infectives) and Manager, Intellectual Property, of MIGENIX, said, "The value of a cost-effective informatics platform that enables rapid and relevant search of the vast universe of sequences and their patents with regard to commercialization of new drugs cannot be understated. This is particularly true in the fast-paced R&D area of infectious disease research. We selected GenomeQuest™ for its ability to instantly locate sequence data and display it in an intuitive and easily-manipulated format."

Ronald Ranauro, President and CEO of GenomeQuest, Inc., said, "With the exponential growth of available sequence data worldwide, having the capability to swiftly research a promising new therapeutic - or defend the IP of an existing one - is rapidly becoming a major competitive advantage in commercialization of drugs. We are very pleased to be able to offer GenomeQuest™'s services to MIGENIX in support of their drug development efforts."

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with U.S. operations in San Diego, California.

Additional information can be found at www.migenix.com.

About GenomeQuest, Inc.

GenomeQuest, Inc.'s innovative sequence search technology provides relevant answers to questions about the human genome asked by scientists and attorneys today, and by clinicians and physicians in the future. The company's flagship product, GenomeQuest™, is an easy-to-use Web-based application that integrates, mines and analyzes sequence data from dozens of scientific and patent sources worldwide. GenomeQuest™'s proprietary sequence analysis capabilities help the world's leading pharmaceutical and biotechnology companies make faster and more accurate decisions on their gene and protein discoveries. Its automated alerting, report publishing and knowledge-sharing capabilities enhance the productivity of all users. GenomeQuest, Inc. is headquartered in Westborough, Massachusetts. For more information, please call (508) 616-0100, or visit our web site: www.genomequest.com.